| 主权项 |
1. A prodrug comprising
(i) at least a first pharmaceutically and/or diagnostically active compound, (ii) at least a second pharmaceutically and/or diagnostically active compound, (iii) two or more cleavable linkers, and (iv) a protein-binding moiety, wherein the first and the second pharmaceutically and/or diagnostically active compounds are each bound to a cleavable linker, and wherein the first and the second pharmaceutically and/or diagnostically active compounds are different from each other, wherein the first pharmaceutically and/or diagnostically active compound is a cytokine, wherein the two or more cleavable linkers can independently be cleaved hydrolytically and/or enzymatically and/or pH-dependently, and wherein the protein-binding moiety binds in situ to cysteine-34 of albumin and is selected from the group consisting of a maleinimide group, a halogenacetamide group, a halogenacetate group, a pyrildylthio group, a vinylcarbonyl group, an aziridin group, a disulfide group, an substituted or unsubstituted acetylene group, or an N-hydroxysuccininide ester group. |
